Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms
- 1 May 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (5), 2401-2404
- https://doi.org/10.1128/aac.02580-12
Abstract
We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical anaerobic isolates using CLSI methods. The GSK MIC50/MIC90 for all isolates tested were 2 and 4 μg/ml, and the MIC90s against 302 Bacteroides fragilis and Bacteroides thetaiotaomicron strains were 4 and 8 μg/ml, respectively. All Clostridium perfringens strains had GSK2251052 MICs of >32 μg/ml. There was no relationship between increased MICs for any other antibiotics and that of GSK2251052.Keywords
This publication has 3 references indexed in Scilit:
- Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2013
- Antibiotics in development targeting protein synthesisAnnals of the New York Academy of Sciences, 2011
- Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical InfectionsJournal of Clinical Microbiology, 2006